Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

68.22 +1.88 (+2.83%)
Streaming Delayed Price Updated: 1:57 PM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
News headline image
Fortrea, Alignment Healthcare, PacBio, DexCom, and Humana Stocks Trade Up, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ... 
Via StockStory
Topics Economy Stocks
News headline image
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment ↗
EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships. 
Via The Motley Fool
News headline image
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement ↗
This medical technology firm delivers advanced noninvasive monitoring and automation solutions to healthcare providers worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
DexCom Inc (NASDAQ:DXCM): A Prime Example of Growth at a Reasonable Price ↗
Via Chartmill
Dexcom Inc (NASDAQ:DXCM) Beats Q4 Profit Estimates Despite Revenue Shortfall ↗
Via Chartmill
News headline image
This Internet Infrastructure Stock Plunged 72% in a Year, so Why Did an Investor Buy Up $12 Million? ↗
Cogent Communications delivers high-speed internet and data center services to commercial clients across multiple continents. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Sotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals ↗
Sotera Health delivers sterilization and lab testing services to regulated industries worldwide, supporting critical supply chains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Growth Stocks to Hold for the Next Decade ↗
They are down, but they are not out. 
Via The Motley Fool
Topics World Trade
News headline image
Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea... 
Via StockStory
Topics Economy
Which S&P500 stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
1 Nasdaq 100 Stock with Impressive Fundamentals and 2 We Avoid
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing. Some are dealing with declining demand, high costs, or regulatory pressures that... 
Via StockStory
News headline image
Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars ↗
It's another reason to invest in this exciting medical device stock. 
Via The Motley Fool
News headline image
The Great Unlocking: Medtronic’s Strategic Pivot and the MiniMed Spin-Off
Date: February 24, 2026 By: Financial Research Analyst Introduction For years, Medtronic plc (NYSE: MDT) was viewed by Wall Street as a reliable but sluggish giant—a "Dividend Aristocrat" that offered... 
Via Finterra
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The 5 Most Interesting Analyst Questions From DexCom’s Q4 Earnings Call
DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day... 
Via StockStory
Topics Earnings
News headline image
Insulet (PODD) Shakes the Market with Q4 Earnings Beat as Omnipod 5 Dominance Continues
Insulet Corporation (NASDAQ:PODD) delivered a commanding performance in its fourth-quarter earnings report released today, February 18, 2026. The medical device leader announced an adjusted earnings... 
Via MarketMinute
Topics Earnings
Top S&P500 movers in Friday's session ↗
Via Chartmill
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Why Is DexCom (DXCM) Stock Rocketing Higher Today
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for both... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment. 
Via The Motley Fool
News headline image
DXCM Q4 Deep Dive: New Product Launches and International Strategy Drive Outlook
Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s... 
Via StockStory
News headline image
DexCom (DXCM) Q4 2025 Earnings Call Transcript ↗
DexCom (DXCM) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Economy
News headline image
DexCom (NASDAQ:DXCM) Exceeds Q4 CY2025 Expectations
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be... 
Via StockStory
News headline image
Earnings To Watch: DexCom (DXCM) Reports Q4 Results Tomorrow
Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 High-Flying Stock with Impressive Fundamentals and 2 We Ignore
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
3 Profitable Stocks for Long-Term Investors
Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline. 
Via StockStory
News headline image
2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
News headline image
Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting... 
Via MarketMinute
Topics Economy
News headline image
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an... 
Via MarketMinute
Topics Earnings Economy
News headline image
1 Growth Stock Down 19% to Buy Right Now ↗
It has had strong momentum since November, but there is still plenty of upside left. 
Via The Motley Fool
Topics Product Recall
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.